Skip to main content

Table 1 Clinical conditions of the patients at admission (Group 1: Early treatment with FPV and HQ, Group 2: Late treatment with FPV and HQ, Group 3: Treatment with only HQ)

From: Benefits of treatment with favipiravir in hospitalized patients for COVID-19: a retrospective observational case–control study

 

Group 1

Group 2

Group 3

p-value

Symptoms before admission to hospital (mean [SD] days)

4.73 (2.447)

3.73(2.141)

2.667 (2.628)

NS

Drugs use

 

 Anti-hypertensive

20 (41.7%)

17 (35.4%)

20 (41.7%)

NS

 Anti-diabetic

19 (39.6%)

13 (27.1%)

14 (29.2%)

NS

Symptoms in admission to hospital

 Fatigue

25(52.1%)

35(72.9%)

22 (45.8%)

NS

 Fever

19 (39.5)

7 (%14.5)

7 (%14.5)

NS

 Cough

30(62.5%)

39 (81.2%)

20 (41.7%)

NS

 Shortness of breath

28 (58.3%)

24 (50.0%)

6 (12.5%)

NS

 Nasal congestion

2 (4.2%)

2 (4.2%)

1 (2.1%)

NS

 Sore throat

9 (18.8%)

10 (20.8%)

8 (16.7%)

NS

 Nausea and vomiting

4 (8.3%)

13 (27.1%)a

5 (10.4%)a

0.020a

 Headache

16b (33.3%)

19c (39.6%)

4b,c (8.3%)

0.001b

0.001c

 Anosmia

4(8.3%)

1(2.1%)

0 (0.0%)

NS

 Diarrhea

5(10.4%)

6 (12.5%)

5 (10.4%)

NS

FPV received after symptoms onset (mean [SD] days)

4.73(2.447)

8.60 (3.654)

 

 < 0.001

  1. Statistically significant values are presented in bold. Superscript letters define the significant p-values of pairwise comparisons. 
  2. FPV Favipiravir; NS: non-significant
  3. a denotes the comparison of patients with nausea and vomiting in Group 2 vs. Group 3
  4. b denotes the comparison of patients with headache in Group 1 vs. Group 3
  5. c denotes the comparison of patients with headache in Group 2 vs. Group 3